Search Results - "Manfrini, Marianna"

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials by Kappos, Ludwig, Wolinsky, Jerry S, Giovannoni, Gavin, Arnold, Douglas L, Wang, Qing, Bernasconi, Corrado, Model, Fabian, Koendgen, Harold, Manfrini, Marianna, Belachew, Shibeshih, Hauser, Stephen L

“…Accumulation of disability in multiple sclerosis may occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA),…”
Get more information

Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes by Yiu, Sean, Wang, Qing, Mercier, Francois, Manfrini, Marianna, Koendgen, Harold, Kletzl, Heidemarie, Model, Fabian

“…In clinical development, it is useful to characterize the causal relationship between individual drug concentrations and clinical outcomes in large phase III…”
Get full text

Recurrent disability progression endpoints in multiple sclerosis clinical trials by Bühler, Alexandra, Wolbers, Marcel, Model, Fabian, Wang, Qing, Belachew, Shibeshih, Manfrini, Marianna, Lorscheider, Johannes, Kappos, Ludwig, Beyersmann, Jan

“…Background: The current standard endpoint to assess disability accumulation in multiple sclerosis (MS) clinical trials is the time to the first confirmed…”
Get full text

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study by Bar-Or, Amit, Calkwood, Jonathan C., Chognot, Cathy, Evershed, Joanna, Fox, Edward J., Herman, Ann, Manfrini, Marianna, McNamara, John, Robertson, Derrick S., Stokmaier, Daniela, Wendt, Jeanette K., Winthrop, Kevin L., Traboulsee, Anthony

“…OBJECTIVEThe phase IIIb A Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Participants With Relapsing Forms of Multiple Sclerosis (VELOCE)…”
Get full text

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial by Wolinsky, Jerry S, Arnold, Douglas L, Brochet, Bruno, Hartung, Hans-Peter, Montalban, Xavier, Naismith, Robert T, Manfrini, Marianna, Overell, James, Koendgen, Harold, Sauter, Annette, Bennett, Iain, Hubeaux, Stanislas, Kappos, Ludwig, Hauser, Stephen L

“…The safety and efficacy of ocrelizumab in primary progressive multiple sclerosis were shown in the phase 3 ORATORIO trial. In this study, we assessed the…”
Get full text

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension by Hauser, Stephen L., Kappos, Ludwig, Arnold, Douglas L., Bar-Or, Amit, Brochet, Bruno, Naismith, Robert T., Traboulsee, Anthony, Wolinsky, Jerry S., Belachew, Shibeshih, Koendgen, Harold, Levesque, Victoria, Manfrini, Marianna, Model, Fabian, Hubeaux, Stanislas, Mehta, Lahar, Montalban, Xavier

“…OBJECTIVETo assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety…”
Get full text

020  Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years by Giovannoni, Gavin, Kappos, Ludwig, Seze, Jerome de, Hauser, Stephen L, Overell, James, Koendgen, Harold, Prajapati, Kalpesh, Manfrini, Marianna, Wang, Qing, Wolinsky, Jerry S

“…BackgroundEfficacy/safety of ocrelizumab in relapsing multiple sclerosis were demonstrated in the OPERA I/II (NCT01247324/NCT01412333) double-blind period…”
Get full text

031  Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years by Schmierer, Klaus, Wolinsky, Jerry S, Brochet, Bruno, Hartung, Hans-Peter, Naismith, Robert, Koendgen, Harold, Manfrini, Marianna, Sauter, Annette, Prajapati, Kalpesh, Kappos, Ludwig

“…BackgroundEfficacy/safety of ocrelizumab in primary progressive multiple sclerosis were demonstrated in the ORATORIO (NCT01194570) double-blind period (DBP)…”
Get full text

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials by Giovannoni, Gavin, Kappos, Ludwig, Seze, Jerome, Hauser, Stephen L., Overell, James, Koendgen, Harold, Manfrini, Marianna, Wang, Qing, Wolinsky, Jerry S.

“…Background and purpose Requiring a walking aid is a fundamental milestone in multiple sclerosis (MS), represented by an Expanded Disability Status Scale (EDSS)…”
Get full text

Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002) by Stokmaier, Daniela, Winthrop, Kevin, Chognot, Cathy, Evershed, Joanna, Manfrini, Marianna, McNamara, John, Bar-Or, Amit

“…Abstract only…”
Get full text

ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial by Hartung, Hans-Peter, Berger, Thomas, Bermel, Robert A., Brochet, Bruno, Carroll, William M., Holmøy, Trygve, Karabudak, Rana, Killestein, Joep, Nos, Carlos, Patti, Francesco, Perrin Ross, Amy, Vanopdenbosch, Ludo, Vollmer, Timothy, Buffels, Regine, Garas, Monika, Kadner, Karen, Manfrini, Marianna, Wang, Qing, Freedman, Mark S.

“…Introduction Ocrelizumab is an approved intravenously administered anti-CD20 antibody for multiple sclerosis (MS). The safety profile and patient preference…”
Get full text

Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290) by Benedict, Ralph, de Seze, Jerome, Hauser, Stephen L., Hartung, Hans-Peter, Kappos, Ludwig, Overell, James, Koendgen, Harold, Wang, Qing, Sauter, Annette, Manfrini, Marianna, Cohan, Stanley

“…Abstract only…”
Get full text

Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data (1807) by Wolinsky, Jerry S., Brochet, Bruno, Hartung, Hans-Peter, Naismith, Robert T., Airas, Laura, Coutant, Karine, Koendgen, Harold, Manfrini, Marianna, Overell, James, Sauter, Annette, Prajapati, Kalpesh, Kappos, Ludwig

“…Abstract only…”
Get full text

Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (1847) by Giovannoni, Gavin, Kappos, Ludwig, de Seze, Jerome, Hauser, Stephen, Overell, James, Koendgen, Harold, Prajapati, Kalpesh, Manfrini, Marianna, Wang, Qing, Wolinsky, Jerry

“…Abstract only…”
Get full text

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis by Hauser, Stephen L., Bar-Or, Amit, Weber, Martin S., Kletzl, Heidemarie, Günther, Andreas, Manfrini, Marianna, Model, Fabian, Mercier, Francois, Petry, Claire, Wing, Qing, Koendgen, Harold, Smith, Terence, Kappos, Ludwig

“…Ocrelizumab improved clinical and MRI measures of disease activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses…”
Get full text

Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091) by Giovannoni, Gavin, Airas, Laura, Bove, Riley, Boyko, Alexey, Cutter, Gary, Hobart, Jeremy, Kuhle, Jens, Oh, Jiwon, Tur, Carmen, Garas, Monika, Model, Fabian, Manfrini, Marianna, Wolinsky, Jerry S.

“…Abstract only…”
Get full text

Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO Trials (2420) by Bar-Or, Amit, Thanei, Gian-Andrea, Harp, Christopher, Cross, Anne, Fiore, Damian, Hauser, Stephen, Jia, Xiaoming, Kappos, Ludwig, Koendgen, Harold, Kuhle, Jens, Leppert, David, Manfrini, Marianna, Model, Fabian, Sauter, Annette, Herman, Ann

“…Abstract only…”
Get full text

Effect of Ocrelizumab on Thalamic Atrophy in Patients with Relapsing and Primary Progressive Multiple Sclerosis (1286) by Arnold, Douglas L., Sprenger, Till, Bar-Or, Amit, Wolinsky, Jerry S., Kappos, Ludwig, Kolind, Shannon, Manfrini, Marianna, Magon, Stefano, van Beek, Johan, Koendgen, Harold, Bernasconi, Corrado, Gaetano, Laura, Traboulsee, Anthony

“…Abstract only…”
Get full text

Blood Neurofilament Light Chain Levels and Association with Brain Volume Change in Patients with Primary Progressive Multiple Sclerosis and Relapsing Multiple Sclerosis Before and During Ocrelizumab Treatment (3926) by Jia, Xiaoming, Herman, Ann, Harp, Christopher, Cross, Anne, Fiore, Damian, Hauser, Stephen, Kappos, Ludwig, Koendgen, Harold, Kuhle, Jens, Leppert, David, Manfrini, Marianna, Model, Fabian, Oksenberg, Jorge, Sauter, Annette, Thanei, Gian-Andrea, Bar-Or, Amit

“…Abstract only…”
Get full text

Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (P1.366) by Hauser, Stephen, Brochet, Bruno, Montalban, Xavier, Naismith, Robert, Wolinsky, Jerry, Manfrini, Marianna, Garas, Monika, Villoslada, Pablo, Model, Fabian, Hubeaux, Stanislas, Kappos, Ludwig

“…Abstract only…”
Get full text